JP6553075B2 - さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体 - Google Patents

さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体 Download PDF

Info

Publication number
JP6553075B2
JP6553075B2 JP2016555467A JP2016555467A JP6553075B2 JP 6553075 B2 JP6553075 B2 JP 6553075B2 JP 2016555467 A JP2016555467 A JP 2016555467A JP 2016555467 A JP2016555467 A JP 2016555467A JP 6553075 B2 JP6553075 B2 JP 6553075B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
eotaxin
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016555467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508461A5 (enExample
JP2017508461A (ja
Inventor
モル，アディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemomab Ltd
Original Assignee
Chemomab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemomab Ltd filed Critical Chemomab Ltd
Publication of JP2017508461A publication Critical patent/JP2017508461A/ja
Publication of JP2017508461A5 publication Critical patent/JP2017508461A5/ja
Application granted granted Critical
Publication of JP6553075B2 publication Critical patent/JP6553075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2016555467A 2014-03-04 2015-03-04 さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体 Active JP6553075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947852P 2014-03-04 2014-03-04
US61/947,852 2014-03-04
PCT/IL2015/050234 WO2015132790A2 (en) 2014-03-04 2015-03-04 Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines

Publications (3)

Publication Number Publication Date
JP2017508461A JP2017508461A (ja) 2017-03-30
JP2017508461A5 JP2017508461A5 (enExample) 2018-03-15
JP6553075B2 true JP6553075B2 (ja) 2019-08-07

Family

ID=52815066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555467A Active JP6553075B2 (ja) 2014-03-04 2015-03-04 さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体

Country Status (11)

Country Link
US (2) US10246508B2 (enExample)
EP (2) EP4155317A1 (enExample)
JP (1) JP6553075B2 (enExample)
CN (1) CN106103479B (enExample)
BR (1) BR112016020366B1 (enExample)
DK (1) DK3114139T3 (enExample)
ES (1) ES2926700T3 (enExample)
IL (1) IL247219B (enExample)
PT (1) PT3114139T (enExample)
RU (1) RU2705255C2 (enExample)
WO (1) WO2015132790A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183028A1 (en) * 2016-04-18 2017-10-26 Chemomab Ltd. Eotaxin-2 inhibitors in the treatment of fibromyalgia
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018139404A1 (ja) 2017-01-24 2018-08-02 協和発酵キリン株式会社 放射線障害の治療又は予防剤並びに治療又は予防方法
GB201702500D0 (en) 2017-02-16 2017-04-05 Univ Sheffield Stable vamp reporter assay
IL251024A0 (en) * 2017-03-08 2017-06-29 Chemomab Ltd Antibodies against eutaxin 2 for use in the treatment of liver diseases
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113613612B (zh) 2019-03-08 2022-08-02 奥瑞斯健康公司 用于医疗系统和应用的倾斜机构
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230192836A1 (en) 2020-04-20 2023-06-22 Chemomab Ltd. Ccl24 inhibitors in the treatment of covid-19
CA3172627A1 (en) * 2020-04-22 2021-10-28 Adi Mor Method of treatment using anti-ccl24 antibody
WO2021219871A2 (en) * 2020-04-30 2021-11-04 Aduro Biotech Holdings, Europe B.V. Anti-cd103 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303736B1 (it) * 1998-11-11 2001-02-23 San Raffaele Centro Fond Peptidi derivati da rantes con attivita' anti-hiv.
EP2046740B1 (en) * 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
CN102307899A (zh) * 2009-01-28 2012-01-04 特拉维夫医学中心医学研究,基础设施及健康服务基金 炎症、自身免疫疾病和心血管疾病的嗜酸细胞活化趋化因子-2(ccl24)抑制剂
AU2010286516B2 (en) * 2009-08-28 2016-10-06 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple CC chemokines
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid

Also Published As

Publication number Publication date
IL247219A0 (en) 2016-09-29
BR112016020366B1 (pt) 2024-01-02
ES2926700T3 (es) 2022-10-27
WO2015132790A3 (en) 2015-11-05
DK3114139T3 (da) 2022-09-12
EP3114139B1 (en) 2022-06-15
PT3114139T (pt) 2022-09-13
RU2016136639A3 (enExample) 2018-05-04
US10246508B2 (en) 2019-04-02
RU2016136639A (ru) 2018-04-05
IL247219B (en) 2021-09-30
WO2015132790A2 (en) 2015-09-11
CN106103479B (zh) 2019-12-24
US10479830B2 (en) 2019-11-19
JP2017508461A (ja) 2017-03-30
US20190153088A1 (en) 2019-05-23
EP4155317A1 (en) 2023-03-29
BR112016020366A2 (pt) 2018-06-05
RU2705255C2 (ru) 2019-11-06
CN106103479A (zh) 2016-11-09
EP3114139A2 (en) 2017-01-11
US20160368979A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
JP6553075B2 (ja) さらなるｃｃｒ３−結合ケモカインを認識する抗エオタキシン−２抗体
TWI857389B (zh) 治療發炎症狀的方法
US10047156B2 (en) Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
US10364296B2 (en) Antibodies specific for MMP9
WO2019042285A1 (zh) 抗cd47抗体及其用途
JP2023537422A (ja) Ｉｌ－１１の抗体及びその使用
JP2024532709A (ja) Ｉｌ－１１ヒト化抗体及びその用途
US20240084019A1 (en) Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications
AU2016293391A1 (en) Humanized anti-S100A9 antibody and uses thereof
JP2015518368A (ja) ＩＬ‐１β中和ヒトモノクローナル抗体
US20220372126A1 (en) Anti ccl24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
CN117003877A (zh) Prdx1 IgG中和抗体及其制备方法和在制备急性器官损伤或脓毒症药物中的应用
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
JP2023533658A (ja) 急性呼吸窮迫症候群を治療又は予防する方法
US20230192836A1 (en) Ccl24 inhibitors in the treatment of covid-19
US20220073600A1 (en) Methods for treating disease using psmp antagonists
WO2024224915A1 (ja) 抗ヒトｃｄ３００ａモノクローナル抗体およびその抗原結合性断片
EA049261B1 (ru) Гуманизированные антитела против хемокин-подобного рецептора 1 и их терапевтические применения
WO2017183028A1 (en) Eotaxin-2 inhibitors in the treatment of fibromyalgia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190703

R150 Certificate of patent or registration of utility model

Ref document number: 6553075

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250